
Please try another search
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Eva Lilienberg | 69 | 2021 | Independent Director |
Thomas Pollare | 72 | 2017 | Chairman |
Ragnar Linder | 72 | 2017 | Independent Director |
John Harrison | - | - | Scientific Advisor |
Sven Ove Ogren | - | - | Scientific Advisor |
Peter Jeffrey Snyder | - | - | Scientific Advisor |
Henrik Zetterberg | - | - | Scientific Advisor |
Bengt Winblad | - | - | Scientific Advisor |
Rolf Karlsten | - | - | Scientific Advisor |
Janet Hoogstraate | 58 | 2023 | Independent Director |
Jan M. Lundberg | 71 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review